- Home
- TOP vs CUE Comparison
TOP vs CUE Comparison
Compare TOP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 49.6M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TOP | CUE |
|---|---|---|
| Price | $1.05 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 51.6K | ★ 1.6M |
| Earning Date | 01-20-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,355,086.00 | ★ $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.48 | N/A |
| 52 Week Low | $0.94 | $0.23 |
| 52 Week High | $3.33 | $1.54 |
Technical Indicators
Market Signals| Indicator | TOP | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 44.17 |
| Support Level | $0.95 | $0.28 |
| Resistance Level | $1.08 | $0.40 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 50.00 | 34.74 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.